Here’s What UBS Thinks About Eli Lilly and Company (LLY)

Group 1 - Eli Lilly and Company (NYSE:LLY) is recognized as one of the best unstoppable growth stocks to buy, with a recent price target increase from $1,080 to $1,250 by UBS, driven by the company's leadership in the obesity treatment market [1] - The anticipated approval of the obesity drug Orfo is expected to significantly impact the company's performance in 2026, with regulatory approval filed in early December [2] - Medicare coverage for obesity treatments is expected to begin in 2026, which is anticipated to enhance the adoption of Eli Lilly's approved and upcoming obesity treatments [2] Group 2 - Leerink Partners also raised the price target for Eli Lilly from $1,104 to $1,234, maintaining a Buy rating, citing the upcoming launch of Orfo as a key factor for the company's long-term potential [3] - Eli Lilly operates as a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing medicines for major health challenges [3]